BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16313878)

  • 21. Optimizing biological therapy in Crohn's disease.
    Gecse KB; Végh Z; Lakatos PL
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What's new: innovative concepts in inflammatory bowel disease.
    Sandborn WJ
    Colorectal Dis; 2006 May; 8 Suppl 1():3-9. PubMed ID: 16594957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?
    Burakoff R
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S202-3. PubMed ID: 18816760
    [No Abstract]   [Full Text] [Related]  

  • 25. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Conservative therapy of inflammatory bowel diseases].
    Nagy F
    Orv Hetil; 2002 Dec; 143(50):2763-8. PubMed ID: 12583315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance drugs for inflammatory bowel disease.
    Drug Ther Bull; 2001 Dec; 39(12):91-5. PubMed ID: 11799594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in Pediatric Inflammatory Bowel Disease.
    Maxwell EC; Grossman AB
    Adolesc Med State Art Rev; 2016; 27(1):57-74. PubMed ID: 27363233
    [No Abstract]   [Full Text] [Related]  

  • 29. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.
    Hibi T; Iwao Y; Yajima T; Inoue N; Ueno Y; Takaishi H; Watanabe M; Ishii H
    J Gastroenterol; 1995 Nov; 30 Suppl 8():121-3. PubMed ID: 8563872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacologic therapy of Crohn's disease and ulcerative colitis].
    Banai J
    Orv Hetil; 2000 May; 141(22):1171-7. PubMed ID: 10853345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
    Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
    Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving medical therapies for ulcerative colitis.
    Cohen RD
    Curr Gastroenterol Rep; 2002 Dec; 4(6):497-505. PubMed ID: 12441040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How important is onset of action in ulcerative colitis therapy?
    Masson S; Nylander D; Mansfield JC
    Drugs; 2005; 65(15):2069-83. PubMed ID: 16225364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Classical medications in the treatment of inflammatory bowel diseases].
    Duvnjak M; Bilić A; Barsić N; Tomasić V; Stojsavljević S
    Acta Med Croatica; 2013 Apr; 67(2):111-24. PubMed ID: 24471294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inducing remission in inflammatory bowel disease.
    Drug Ther Bull; 2003 Apr; 41(4):30-2. PubMed ID: 12724846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.